Capital One Initiates Coverage On Protagonist Therapeutics with Overweight Rating

Protagonist Therapeutics, Inc. +2.85%

Protagonist Therapeutics, Inc.

PTGX

28.48

+2.85%

Capital One analyst Tim Chiang initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Overweight rating.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via